Phase 3 Readout
CSTL: Phase 3 Topline: A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Re
July 1, 2037 · fcx-007. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 1, 2037
- Company
- Castle Biosciences Inc. (CSTL)
- Drug
- fcx-007
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Re
- Drug
- fcx-007
- Indication
- Recessive Dystrophic Epidermolysis Bullosa